NSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Insperity Inc (NSP) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While insider buying and hedge fund interest are positive signals, the company's financial performance, mixed analyst ratings, and lack of strong technical or proprietary trading signals suggest a cautious approach. The stock may face short-term headwinds, and the investor's impatience and unwillingness to wait for optimal entry points make it unsuitable for immediate investment.
The MACD is positive at 1.224, indicating bullish momentum, but it is contracting. RSI is at 76.214, which is neutral. Moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 27.064), suggesting limited upside potential in the short term. Historical stock trend analysis predicts a potential decline of -1.89% in the next week and -6.26% in the next month.
Significant insider buying by CEO Paul J. Sarvadi, reflecting confidence in the company's future.
Hedge fund buying activity has increased by 247.65% over the last quarter.
Analysts from Roth Capital maintain a Buy rating, citing potential profit improvement in 2026 and growth acceleration in 2027.
Mixed analyst ratings with some downgrades and reduced price targets due to uncertainty in healthcare costs and stagnant small business hiring.
Gross margin dropped significantly by -25.25% YoY in Q4
The stock's historical trend suggests potential short-term declines.
In Q4 2025, revenue increased by 3.41% YoY to $1.668 billion. Net income improved significantly but remained negative at -$33 million, up 266.67% YoY. EPS also improved but stayed negative at -0.87, up 262.50% YoY. Gross margin dropped to 9.59%, down -25.25% YoY, indicating cost pressures.
Analyst sentiment is mixed. Roth Capital maintains a Buy rating with a reduced price target of $56, citing profit improvement and growth potential in 2026-2027. JPMorgan and Baird analysts have Neutral and Underweight ratings, respectively, with lowered price targets due to concerns about healthcare costs and hiring trends.
